Navigation Links
InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
Date:9/16/2008

Morhet, Chairman and Chief Executive Officer. "I'm pleased with our scientific progress, regulatory plans and soon we'll be well positioned to begin formal discussions with the FDA."

About DXL(TM) Technology Platform

DXL(TM) technology works by integrating self-binding peptides into monoclonal antibodies, potentiating target binding. Modified antibodies "cluster" upon engaging the target receptor site, resulting in greater "molecular mass" at the point of association. DXL(TM) antibodies have significantly extended dissociation rates, as measured by surface plasmon resonance. As a consequence, this may facilitate cancer cell destruction in a target dependent manner by increasing apoptosis, antibody dependent cell cytotoxicity and complement-dependent cytotoxicity. To learn more about InNexus' DXL(TM) technology, please visit http://www.ixsbio.com.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of new and existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in- house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
3. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
7. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
8. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
9. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... 17 Decision Resources, one of the ... and healthcare issues, finds that the cost of ... and side-effect profile, are cited most frequently by ... of Avastin for non-small-cell lung cancer treatment in ... ,, The new Special European Physician & Payer ...
(Date:12/17/2009)... HUNTINGTON BEACH, California and AMSTERDAM, December 17 /PRNewswire/ ... announced today that,the US Food and Drug Administration ... all ages. MammaPrint is the only FDA-cleared,breast cancer ... the,past three years, the FDA has issued four ... service. , "This FDA ...
(Date:12/17/2009)... Calif., Dec. 17 Frost & ... North American Healthcare Innovation Award in molecular ... for its commitment to providing innovative technologies ... Since its incorporation in 2004, IntelligentMDx has ... approach to make tests that are clinically ...
Breaking Medicine Technology:Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 2Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 3FDA Broadens Clearance for Agendia's MammaPrint(R) 2Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 2Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 3Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 4Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 5More Gene Mutations Linked to Autism Risk 4655 1More Gene Mutations Linked to Autism Risk 4655 2More Gene Mutations Linked to Autism Risk 4655 3More Gene Mutations Linked to Autism Risk 4655 4HIV Testing Day Set for Saturday in U S 50162 1Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 1Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 2Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 3
... EPOC Results Published in March 22 Issue ... March 20 Sanofi-aventis,today announced that efficacy ... Intergroup study published in the March 22 ... patients Eloxatin(R) (oxaliplatin injection) in,combination with 5-fluorouracil/leucovorin ...
... targeting interleukin-6 receptors, ACTEMRA provides significant ... existing therapies -, NUTLEY, N.J., March 20 ... (tocilizumab) experienced,significant and rapid reduction in the signs ... published in this week,s issue of The Lancet. ...
Other Medicine Technology:Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 2Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 3Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 4Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 5International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet 2International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet 3International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet 4International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet 5
(Date:12/17/2009)... heels of unveiling the new Stadium to the Sea ... officials today announced a larger-than-ever charity program that will ... from cancer research to gang intervention to cleaning up ... line with the vision of Marathon Owner Frank McCourt, ... a huge philanthropic force in the community. McCourt envisions ...
(Date:12/17/2009)... The following feature is by Devon Herrick, PhD, ... ,, People often assume they have little control ... After all, sickness cannot be scheduled, doctors prescribe treatments ... percent of Americans. However, there are many overlooked ways ... care you need. ,, Cut your ...
(Date:12/17/2009)... DAYTON, Ohio, Dec. 17 Good Samaritan Hospital ... pelvic health issues with the launch of the Good ... ,, The center is designed to help treat two ... incontinence) and slippage of the bladder, uterus or rectum ... some degree of urinary leakage and one out of ...
(Date:12/17/2009)... -- The National Council on Disability (NCD) ... Marriott Houston, 5150 Westheimer, Houston, TX, beginning at 8:30 ... 11:00 a.m. on Thursday, January 21, 2010. This meeting ... it is vital to hear from communities around the ... people with disabilities. This meeting will provide another opportunity ...
(Date:12/17/2009)... show that Chinese research output has increased from just ... 2008. , Faculty of 1000, which selects only ... more than 530 papers from Chinese universities and institutes ... in 2004, this increased by over fourfold in 2008 ... , Jane Hunter, Managing Director of Faculty of 1000, ...
Breaking Medicine News(10 mins):Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 2Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 3Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 4Health News:Six Ways to Slash Your Health Costs 2Health News:Six Ways to Slash Your Health Costs 3Health News:Six Ways to Slash Your Health Costs 4Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 2Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 3Health News:National Council on Disability to Hold Houston Meeting to Hear Issues Affecting People With Disabilities 2Health News:China rapidly catching up in research impact 2
... invites customers to just ,have fun, and use social ... 6 Baxa Corporation, a leading developer of technology ... medications, has joined the social media craze by hosting ... Group. More and more healthcare facilities, medical device ...
... MULTIPLE LIFESTYLE-BASED OFFERINGSLOS ANGELES, April 6 ... FVRL), which through its wholly-owned operating subsidiary, ... Personal Health Records ("PHRs") ( www.mymedicalrecords.com ... storage solutions ( www.myesafedepositbox.com ), ...
... and B-to-C Firm Starts with Several Accounts; Membership ... 6 Feintuch Communications, Inc. ( www.feintuchcommunications.com ... industry veteran and former journalist Henry Feintuch, has ... Avenue in New York City.(Logo: ...
... 2009 New head-to-head clinical trial results demonstrate that ... The five studies conducted by Johnson & Johnson ... during the 87th General Session and Exhibition of the ... , REACH ULTRACLEAN Floss removes up to two ...
... for the Medical Waste Treatment MarketMOUNTAIN VIEW, Calif., April ... medical waste treatment market, Frost & Sullivan recognizes BioMedical ... Frost & Sullivan Award for Product Innovation of the ... innovation, as evidenced by its introduction of the Demolizer(R) ...
... EL SEGUNDO, Calif., April 6 DaVita ... named winner of the 2009 Recruiting Department of the ... ( http://www.ere.net ) presents Recruiting Excellence Awards annually to ... (Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO )The ...
Other Medicine News:Health News:Baxa Corporation Gets Social With Facebook and LinkedIn 2Health News:Baxa Corporation Gets Social With Facebook and LinkedIn 3Health News:MMR Information Systems, Inc. Joins With United Marketing Group to Offer Its MyMedicalRecords Personal Health Record and MyEsafeDepositBox Services to Vast Array of Nationally Recognized Partners 2Health News:MMR Information Systems, Inc. Joins With United Marketing Group to Offer Its MyMedicalRecords Personal Health Record and MyEsafeDepositBox Services to Vast Array of Nationally Recognized Partners 3Health News:MMR Information Systems, Inc. Joins With United Marketing Group to Offer Its MyMedicalRecords Personal Health Record and MyEsafeDepositBox Services to Vast Array of Nationally Recognized Partners 4Health News:Feintuch Communications Launches as Independent Strategic Relations Firm 2Health News:Feintuch Communications Launches as Independent Strategic Relations Firm 3Health News:Feintuch Communications Launches as Independent Strategic Relations Firm 4Health News:New head-to-head clinical studies reveal Reach Ultraclean toothbrush and floss deliver superior plaque removal compared to leading competitive products 2Health News:BioMedical Technology Solutions, Inc. a Division of BioMedical Technology Solutions Holdings, Inc. Symbol (BMTL) OTCBB Receives Frost & Sullivan's Product Innovation of the Year Award 2Health News:BioMedical Technology Solutions, Inc. a Division of BioMedical Technology Solutions Holdings, Inc. Symbol (BMTL) OTCBB Receives Frost & Sullivan's Product Innovation of the Year Award 3Health News:BioMedical Technology Solutions, Inc. a Division of BioMedical Technology Solutions Holdings, Inc. Symbol (BMTL) OTCBB Receives Frost & Sullivan's Product Innovation of the Year Award 4Health News:DaVita Wins Recruiting Department of the Year Award 2
... SonoVue, a new Contrast ... aqueous suspension of stabilized SF6 ... microbubbles is between 1 and ... is between 2 and 5 ...
... well-established, second-generation ultrasound medical diagnostic product with ... borders of the heart. This allows doctors ... the heart during an ultrasound scanning procedure, ... heart condition and providing guidance for the ...
... new tibial guide is designed for accuracy ... choose between "point" or "elbow" aimers and ... creation of the tibial tunnel. The system ... features and the reproducibility and accuracy gained ...
The Pinn-ACL Guide can be used to create tibial tunnels of known lengths with a variable angle adjustment of 35 to 60 degrees with the use of a,graduated pin-sleeve....
Medicine Products: